Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and glutamine

sorafenib has been researched along with glutamine in 6 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(glutamine)		Trials
(glutamine)		Recent Studies (post-2010) (glutamine)
6,5207305,25119,0627875,408

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY1
Dai, W; Dong, L; Guo, C; Guo, H; Liu, H; Liu, T; Shen, X; Song, G; Weng, S; Xu, L; Yu, X; Zhang, G; Zhu, J1
Gan, B; Koppula, P; Zhuang, L1
Chakraborti, A; Dhiman, RK; Kanthaje, S; Kaur, R; Taneja, S1
Ding, J; Li, D; Lin, B; Luo, J; Shang, M; Wang, W; Xu, K; Zheng, S; Zhou, L1

Reviews

2 review(s) available for sorafenib and glutamine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
    Protein & cell, 2021, Volume: 12, Issue:8

    Topics: Amino Acid Transport System y+; Antineoplastic Agents; Cystine; DNA Methylation; Ferroptosis; Gene Expression Regulation, Neoplastic; Glucose; Glutamine; Glutathione; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Piperazines; Signal Transduction; Sorafenib; Sulfasalazine

2021

Other Studies

4 other study(ies) available for sorafenib and glutamine

ArticleYear
PPARĪ“ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Molecular cancer research : MCR, 2017, Volume: 15, Issue:9

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutamine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; PPAR delta; Random Allocation; Sorafenib; Transfection; Xenograft Model Antitumor Assays

2017
OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
    Journal of hepatology, 2020, Volume: 72, Issue:5

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Drug Resistance, Neoplasm; Female; Gene Silencing; Glutamine; Humans; Ketoglutarate Dehydrogenase Complex; Lipid Metabolism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays

2020
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line.
    Genes, 2022, 08-01, Volume: 13, Issue:8

    Topics: Autophagy; Carcinoma, Hepatocellular; Cell Line; Chloroquine; Gene Expression Regulation, Neoplastic; Glutamine; Humans; Liver Neoplasms; MicroRNAs; Sorafenib

2022
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis.
    Cells, 2022, 12-21, Volume: 12, Issue:1

    Topics: Carcinoma, Hepatocellular; Glutamine; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Sorafenib

2022